Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
August 07, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
July 16, 2024 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
June 06, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 07, 2024 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
April 30, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
February 27, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
January 16, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive...
January 10, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777...
December 19, 2023 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Provides Corporate Update

- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19,...